173 related articles for article (PubMed ID: 24375440)
41. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
42. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
Dean JP; Sprenger CC; Wan J; Haugk K; Ellis WJ; Lin DW; Corman JM; Dalkin BL; Mostaghel E; Nelson PS; Cohen P; Montgomery B; Plymate SR
J Clin Endocrinol Metab; 2013 May; 98(5):E820-8. PubMed ID: 23533230
[TBL] [Abstract][Full Text] [Related]
43. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.
Prapotnich D; Cathelineau X; Rozet F; Barret E; Mombet A; Cathala N; Sanchez-Salas RE; Vallancien G
World J Urol; 2009 Oct; 27(5):627-35. PubMed ID: 19247669
[TBL] [Abstract][Full Text] [Related]
44. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
Knudsen KE; Scher HI
Clin Cancer Res; 2009 Aug; 15(15):4792-8. PubMed ID: 19638458
[TBL] [Abstract][Full Text] [Related]
45. Androgen receptor as a target in androgen-independent prostate cancer.
Balk SP
Urology; 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9. PubMed ID: 12231070
[TBL] [Abstract][Full Text] [Related]
46. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
47. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
[No Abstract] [Full Text] [Related]
48. [Hormonal therapy for prostate cancer: methods and prognosis].
Huang BX; Su HC; Cao WL; Sun FK
Zhonghua Nan Ke Xue; 2013 Sep; 19(9):815-9. PubMed ID: 24386861
[TBL] [Abstract][Full Text] [Related]
49. Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
Hijab A; Taha T; Charas T; Bar-Sela G; Stein P; Agbarya A
Anticancer Drugs; 2022 Jan; 33(1):e747-e751. PubMed ID: 34387605
[TBL] [Abstract][Full Text] [Related]
50. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
51. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
[TBL] [Abstract][Full Text] [Related]
52. Treating the biochemical recurrence of prostate cancer after definitive primary therapy.
Ward JF; Moul JW
Clin Prostate Cancer; 2005 Jun; 4(1):38-44. PubMed ID: 15992460
[TBL] [Abstract][Full Text] [Related]
53. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
54. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Garnick MB
BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
[No Abstract] [Full Text] [Related]
55. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
56. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
Festuccia C; Gravina GL; Muzi P; Pomante R; Ventura L; Ricevuto E; Vicentini C; Bologna M
Prostate; 2007 Sep; 67(12):1255-64. PubMed ID: 17596848
[TBL] [Abstract][Full Text] [Related]
57. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
Schultz NM; Shore ND; Chowdhury S; Klotz LH; Concepcion RS; Penson DF; Karsh LI; Yang H; Brown BA; Barlev A; Flanders SC
BMC Urol; 2018 Sep; 18(1):77. PubMed ID: 30189902
[TBL] [Abstract][Full Text] [Related]
58. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
[TBL] [Abstract][Full Text] [Related]
59. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
60. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
Nakabayashi M; Xie W; Buckle G; Bubley G; Ernstoff MS; Walsh W; Morganstern DE; Kantoff PW; Taplin ME
Urology; 2013 Mar; 81(3):611-6. PubMed ID: 23452809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]